Research Analysts Issue Forecasts for Pharvaris Q2 Earnings

Pharvaris (NASDAQ:PHVS) – Equities research analysts at Wedbush increased their Q2 2025 EPS estimates for shares of Pharvaris in a research report issued to clients and investors on Wednesday, May 14th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.87) per share for the quarter, up from their previous estimate of ($0.93). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.57) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($2.20) EPS and FY2028 earnings at $0.44 EPS.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

A number of other research analysts also recently commented on PHVS. JMP Securities upped their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st. Cantor Fitzgerald dropped their price objective on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday.

Pharvaris Trading Up 4.1%

Shares of PHVS stock opened at $16.56 on Friday. The firm has a 50-day moving average price of $15.38 and a 200 day moving average price of $17.68. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The company has a market capitalization of $865.92 million, a price-to-earnings ratio of -5.91 and a beta of -2.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC purchased a new stake in shares of Pharvaris during the 3rd quarter worth about $106,000. Palumbo Wealth Management LLC purchased a new stake in shares of Pharvaris during the 4th quarter worth about $196,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris during the 4th quarter worth about $111,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after purchasing an additional 2,847 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after purchasing an additional 1,356 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.